Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$28.76
neg -0.68
-2.31%
Today's Range: 28.47 - 29.29 | TEVA Avg Daily Volume: 6,961,400
Last Update: 05/23/17 - 4:02 PM EDT
Volume: 14,880,196
YTD Performance: -18.79%
Open: $29.26
Previous Close: $29.44
52 Week Range: $29.36 - $56.44
Oustanding Shares: 1,016,000,000
Market Cap: 30,358,080,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 5 5 6
Moderate Buy 1 1 1 1
Hold 8 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.50 2.40 2.40 2.31
Latest Dividend: 0.29
Latest Dividend Yield: 3.87%
Dividend Ex-Date: 06/01/17
Price Earnings Ratio: 5.81
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
5.81 0.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-18.15% -43.32% -41.89%
GROWTH 12 Mo 3 Yr CAGR
Revenue 11.50 0.10 0.03
Net Income -80.50 -0.80 -0.37
EPS -96.20 -0.90 -0.64
Earnings for TEVA:
EBITDA 6.18B
Revenue 21.90B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.10 $1.22 $4.69 $4.62
Number of Analysts 5 5 7 6
High Estimate $1.17 $1.33 $5.00 $5.08
Low Estimate $1.06 $1.02 $4.18 $3.99
Prior Year $1.25 $1.28 $5.06 $4.69
Growth Rate (Year over Year) -11.68% -4.69% -7.31% -1.42%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | May 1, 2017 | 2:08 PM EDT
Prices are extended on the downside.
By

Bret Jensen

 | Apr 12, 2017 | 11:00 AM EDT
Acadia and Neurocrine both have catalysts for growth; buy any weakness.
RMPIA
By

Bret Jensen

 | Apr 10, 2017 | 11:30 AM EDT
These stocks should be part of a strong first-quarter earnings season.
By

Bruce Kamich

 | Apr 3, 2017 | 9:47 AM EDT
It will probably take a close above $38 to turn the chart more bullish.
RMPIA
By

Bret Jensen

 | Feb 22, 2017 | 10:00 AM EST
These two large-cap drug giants should be core parts of any well-diversified portfolio.
By

Jim Cramer

 | Feb 7, 2017 | 3:10 PM EST
Yes, he's unpredictable, but is that a reason to sell?
RMPIA
By

Jim Cramer

 | Jan 31, 2017 | 11:18 AM EST
Two industries should largely be avoided under this administration: pharma and retail.

bearishTeva estimates, target reduced at Barclays

Jan 31, 2017 | 7:02 AM EST
Shares of TEVA now seen reaching $38, according to Barclays. Estimates also cut, given generic Copaxone competition.
RMPIA
By

Bret Jensen

 | Jan 24, 2017 | 11:00 AM EST
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
By

David Katz

 | Jan 11, 2017 | 8:00 AM EST
This pharma company is still making lots of money and its stock is too cheap to pass up.
Sally Beauty's CEO put his money to work buying 10,000 shares on the new low today (@ $17....
HD began last Tuesday's session with a huge earnings inspired upside gap. In the early goi...
Bloomberg reported recently that there are now more stock market indexes in the US (more t...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.